Loading stock data…
INSM
$124.89-1.40 (-1.11%)
Market ClosedLast close Sep 8
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insmed Incorporated in the Healthcare sector is trading at $124.89 with a market capitalization of $20.6B. Wall Street consensus targets $200.18 (22 analysts), implying a +60.3% move over the next 12 months. The stock is currently 41% below its 52-week high of $212.75, remaining 11.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +60.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $305.96M↑ | $263.84M↑ | $142.34M↑ | $107.42M↑ | $92.82M |
| Gross Profit | $258.54M↑ | $219.62M↑ | $112.98M↑ | $79.34M↑ | $71.55M |
| Operating Income | -$200.28M↑ | -$249.71M↑ | -$261.35M↓ | -$253.88M↓ | -$229.84M |
| Net Income | -$163.56M↑ | -$328.49M↑ | -$370.02M↓ | -$321.69M↓ | -$256.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial l...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$20.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-167.94%
Volume
Today's trading volume
1.60M
Recent News
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent […]
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 2025, and the net loss shrank from $321.7 million a year ago to just $13.2 million. The numbers tell the story of […]
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Insmed (INSM) Q2 2026 Earnings Call Transcript
BRINSUPRI revenue surged to $309.2 million, driving total revenues to $425.5 million.